Drug intelligence / Profile preview

Donor Enriched Activated Natural Killer cells

Development stage: Phase 1
Lead developer: University of Nebraska Medical Center
Modality: CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Donor Enriched Activated Natural Killer (DEA-NK) cells are an investigational adoptive cellular immunotherapy developed by the University of Nebraska Medical Center for the treatment of refractory myeloid malignancies. The therapy consists of natural killer (NK) cells obtained from a haploidentical (half-matched) donor, which are then enriched and activated ex vivo using cytokines to enhance their anti-leukemic activity and longevity. These activated NK cells are administered intravenously to patients on day +7 following a haploidentical stem cell transplant (Haplo-SCT) that utilizes post-transplant cyclophosphamide (PTCY). The mechanism of action involves natural killer cell-mediated cytotoxicity, where the infused cells directly target and eliminate residual tumor cells in patients with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or myeloproliferative neoplasms (MPN).

Other names: Donor Enriched Activated NK cellsαβ TCR/CD19 depleted (DEA-NK) cells

Targets

NCR2 (Natural cytotoxicity triggering receptor 2)NCR3 (Natural cytotoxicity trigger receptor 3 (NKp30))NCR1 (Natural cytotoxicity triggering receptor 1)NKG2D (Natural killer group 2 member D receptor)FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)

Beyond the preview

Go deeper on Donor Enriched Activated Natural Killer cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Donor Enriched Activated Natural Killer cells.

Explore the full profile